Elevate Clinical Trials with Real-time AI-based Reading Excellence

RetInSight cAIre (“center of AI reading excellence”) delivers cutting-edge AI-based image analysis to enhance performance and quality in clinical trials. With validated biomarker algorithms in diseases such as nAMD, DME & RVO, and GA, we provide real-time solutions that maximize clinical trial efficiency and outcome. Our services cater to pharmaceutical companies, academic researchers, and manual reading centers, ensuring an elevated standard of clinical trial excellence from start to finish.

Unlock the potential of AI-based reading

  • Maximized data value: Automate, quantify, and produce reproducible read-outs to unlock the full value of clinical trial data in real-time
  • Accelerated recruitment: Shorten recruitment timelines and reduce patient visits through efficient image data analysis
  • Optimized workflows: Streamline clinical trial workflows, saving costs and effort while maintaining high quality

Secure, compliant, fully integrated

Our commitment to data security and compliance ensures trust and peace of mind throughout the clinical trial process

  • Secure cloud-based infrastructure: Leverage our industry-leading cloud infrastructure on AWS Europe, ensuring data security and privacy with GCP, GDPR, and HIPAA compliance. Our systems adhere to ISO 27001 standards
  • Seamless Integration: Benefit from our fully integrated solutions that seamlessly integrate with existing PAC systems (Picture Archiving and Communication). This integration enhances efficiency and simplifies workflow processes
  • Global networking: Collaborate with our network of manual reading centers, expanding possibilities for multi-center trials and novel insights into retinal diseases

Digital AI reading center

As a central reading center, RetInSight cAIre develops the software infrastructure that revolutionizes all aspects of clinical trial services, elevating efficiency and outcomes. We target innovative solutions with our partners to provide groundbreaking insights into retinal diseases, advancing the field of retinal research.

Reach out to us today and discover the future of clinical trials, we look forward to hearing from you.

Contact RetInSight

Request a demo of the RetInSight Fluid Monitor

If you are interested to get a demo of the Fluid Monitor, please fill out this short form with your contact details and we will be in touch.

If you have other questions, please contact us.

We look forward to hearing from you.

References

  1. Waldstein SM, Philip AM, Leitner R, Simader C, Langs G, Gerendas BS, Schmidt-Erfurth U. Correlation of 3-Dimensionally Quantified Intraretinal and Subretinal Fluid With Visual Acuity in Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2016 Feb;134(2):182-90. doi: 10.1001/jamaophthalmol.2015.4948. PMID: 26661463.
  2. Gregor S. Reiter et al. Performance of an Artificial Intelligence Decision Support Tool, The Vienna Fluid Monitor in Neovascular Age-Related Macular Degeneration. Presentation at Euretina 2022.
  3. Gerendas, Bianca S. et al. VALIDATION OF AN AUTOMATED FLUID ALGORITHM ON REAL-WORLD DATA OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION OVER FIVE YEARS. Retina 42(9):p 1673-1682, September 2022. | DOI: 10.1097/IAE.0000000000003557.
  4. Chakravarthy, U. et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye 35, 2983–2990 (2021). https://doi.org/10.1038/s41433-020-01354-4
  5. Ursula Schmidt-Erfurth et al. AI-based monitoring of retinal fluid in disease activity and under therapy. Progress in Retinal and Eye Research. Volume 86, 2022, 100972, ISSN 1350-9462, https://doi.org/10.1016/j.preteyeres.2021.100972.
  6. Chaudhary, Varun et al. IMPACT OF FLUID COMPARTMENTS ON FUNCTIONAL OUTCOMES FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Literature Review. Retina 42(4):p 589-606, April 2022. DOI: 10.1097/IAE.0000000000003283.
  7. Aslam, T.M., Mahmood, S., Balaskas, K. et al. Statistical Modelling of the Visual Impact of Subretinal Fluid and Associated Features. Ophthalmol Ther 10, 127–135 (2021). https://doi.org/10.1007/s40123-020-00327-w
  8. Ursula Schmidt-Erfurth et al. Machine Learning to Analyze the Prognostic Value of Current Imaging Biomarkers in Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, Volume 2, Issue 1,2018, Pages 24-30, ISSN 2468-6530. DOI: https://doi.org/10.1016/j.oret.2017.03.015.
  9. Euretina 2021 Clinical Survey Outcomes.
  10. Data on file RetInSight.
  11. Michl M et al. A systematic evaluation of human expert agreement on optical coherence tomography biomarkers using multiple devices. Eye (Lond). 2022 Dec 28. doi: 10.1038/s41433-022-02376-w. Epub ahead of print. PMID: 36577804.

Clinical Decision Support System (CDSS)​

The RetInSight Fluid Monitor is a fully automated comprehensive AI-based Clinical Decision Support System, consisting of:​

  • The artificial intelligence software​
  • The web-based customer portal​
  • The Instruction for Use in the required languages​
  • The secure cloud-based image analysis server​
  • The secured data exchange via internet connection​
  • The cloud-based web service for back-end data storage and maintenance​
  • Compliance with the current EU medical device regulation ​
  • Customer support​

As a CDSS, the RetInSight Fluid Monitor facilitates decision-making in patient management, but it does not provide an autonomous recommendation.​

Request a demo of the RetInSight Fluid Monitor

If you are interested to get a demo of the Fluid Monitor, please fill out this short form with your contact details and we will be in touch.

If you have other questions, please contact us.

We look forward to hearing from you.

​